Hyperthermic intraperitoneal chemotherapy for treating ovarian cancer

This article reviews HIPEC and its targeted intraoperative and postoperative management.
Source: Journal of the American Academy of Physician Assistants - Category: Primary Care Tags: Special Topics in Women's Health Source Type: research

Related Links:

Authors: Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T Abstract Objective: The purpose of the present review was to provide evidence-based guidance about the provision of cytoreductive surgery (crs) with hyperthermic intraperitoneal chemotherapy (hipec) in the treatment of peritoneal cancers. Methods: The guideline was developed by the Program in Evidence-Based Care together with the Surgical Oncology Program at Ontario Health (Cancer Care Ontario) through a systematic review of relevant literature, patient- and caregiver-specific consultation, and internal and external reviews. Results: Re...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Joe Abdo1, Christopher S. Wichman2, Nicholas E. Dietz1,3, Pawel Ciborowski4, John Fleegel1, Sumeet K. Mittal1,5 and Devendra K. Agrawal1* 1Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, United States 2Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States 3Department of Pathology, CHI Health Creighton University Medical Center, College of Medicine, Omaha, NE, United States 4Department of Pharmacology, University of Nebraska Medical Center, Omaha, NE, United States 5Norton Thoracic Institute, St....
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
chel L O’Donnell Dysfunctional homologous recombination DNA repair (HRR), frequently due to BRCA mutations, is a determinant of sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi). In cultures of ovarian cancer cells, we have previously shown that HRR function, based upon RAD51 foci quantification, correlated with growth inhibition ex vivo induced by rucaparib (a PARPi) and 12-month survival following platinum chemotherapy. The aim of this study was to determine the feasibility of measuring HRR dysfunction (HRD) in other tumours, in order to estimate the frequency and hence wid...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionConsidering the patient ’s occupational and environmental history, it is estimated that she had been exposed to asbestos significantly, so we determined that ovarian cancer in the patient is highly correlated with the occupational exposure of asbestos and environmental exposure is a possible cause as well. Social devices are needed to prevent further exposure to asbestos. It is also necessary to recognize that ovarian cancer can occur in workers who have previously been exposed to asbestos, and the education and social compensation for those workers are needed.
Source: Annals of Occupational and Environmental Medicine - Category: Occupational Health Source Type: research
CONCLUSIONS: The risks of perioperative morbidity and mortality after CRS and HIPEC are analogous to any other major gastrointestinal surgery. CRS and HIPEC should remain a treatment option for highly selected patients in whom a curative or life prolonging treatment is a pursuit and should be performed in high volume specialized institutions. PMID: 29589675 [PubMed - as supplied by publisher]
Source: Minerva Chirurgica - Category: Surgery Tags: Minerva Chir Source Type: research
Authors: Lemoine L, Sugarbaker P, Van der Speeten K Abstract Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardization regarding the CRS, we are s...
Source: International Journal of Hyperthermia - Category: Internal Medicine Tags: Int J Hyperthermia Source Type: research
For more than a decade, pulmonologist Dr. Dan Sterman has believed immunotherapy would become the catalyst for major advancements in the treatment of malignant pleural mesothelioma. Today, he is closer than ever to proving that point. Sterman, director of pulmonary medicine at New York University, soon will help launch a multicenter clinical trial involving a powerful immunogene therapy combination that may change the way this deadly asbestos-related cancer is viewed. “I believe that immunotherapy will become the fourth pillar of treatment for mesothelioma (joining chemotherapy, radiation and surgery),&rdquo...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Research & Clinical Trials Source Type: news
Targeting cancer stem cells (CSCs) holds promise to address key challenges of cancer treatment: chemo- and radiation therapy resistance, metastasis, and recurrence. Increased CSC abundance after neoadjuvant chemotherapy has been associated with a significantly worse outcome. Combining CSC-targeted agents with chemotherapy may lead to more durable response with increased overall survival.Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, mediates signal transduction by integrins and growth factor receptors to regulate cellular adhesion, proliferation, migration, and survival. Several studies have demonstrated that...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Cancer Stem Cells: Poster Presentations - Proffered Abstracts Source Type: research
A phase I study to evaluate the safety and feasibility of an intravenous infusion of autologous T cells transduced to express a chimeric antigen receptor directed against mesothelin (CART-meso) in patients with mesothelin expressing tumors is being conducted at the University of Pennsylvania. Here we report on the first five patients treated with CART-meso T cell infusion.Five patients with recurrent advanced stage cancers (two serous ovarian, two epithelial mesothelioma, and one pancreatic) who had received 4-12 prior regimens, were treated with a single infusion of CART-meso cells. Apheresed autologous T cells were trans...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Clinical Trials Source Type: research
More News: Academies | Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Epithelial Cancer | Mesothelioma | Ovarian Cancer | Ovaries | Primary Care | Toxicology | Women